-
2025-521651-22-00
4
hormone receptor positive, HER2-negative breast cancer
-
2025-521827-61-00
4
refractory/relapsed multiple myeloma
-
2025-522818-23-00
5
Small Cell Lung Cancer (SCLC)
-
2025-522855-25-00
5
Urinary Bladder Neoplasms
-
2025-523735-19-00
5
Metastatic Microsatellite Stable Colorectal Cancer
-
2025-523869-22-00
5
advanced or metastatic extrapulmonary neuroendocrine carcinoma
-
2025-524048-36-00
5
Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcin
-
2025-524077-16-00
4
metastatic urothelial carcinoma
-
2025-524487-37-00
6
Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MP
-
2025-524488-18-00
4
Muscle-invasive Bladder Cancer
-
2025-523815-12-00
5
2026-07-06
Relapsed or Refractory Multiple Myeloma
-
2025-520565-51-00
5
2026-06-23
small cell lung cancer
-
2025-523425-17-00
4
2026-06-03
Proteinuric kidney diseases
-
2025-522981-61-00
4
2026-05-19
endometrial cancer
-
2025-523180-38-00
4
2026-05-12
Uncontrolled Moderate to Severe Eosinophilic Asthma
-
2025-520660-18-00
6
2026-05-08
Heart Failure
-
2024-519818-31-01
5
2026-04-10
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2025-522553-19-00
10
2026-02-25
Symptomatic genetic and familial dilated cardiomyopathy.
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2024-520433-76-00
4
2026-01-08
Newly Diagnosed Multiple Myeloma
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-